Telix Pharmaceuticals Limited announced unaudited revenue results for the fourth quarter and full fiscal year 2023. The company reported $148.1 million (USD 97.1 million) of total product revenue, primarily generated from sales of Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) in the United States, an increase of 11% on the prior quarter (Q3 2023) total revenue of $133.6 million (USD 87.2 million).

The total revenue (unaudited) for Fiscal Year 2023 is $502.5 million (USD 333.0 million).